skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: tipo de recurso: Anais de Congresso remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
On understanding the figures of merit for detection and measurement of x-ray polarization
On understanding the figures of merit for detection and measurement of x-ray polarization
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

On understanding the figures of merit for detection and measurement of x-ray polarization

WEISSKOPF, Martin C ; ELSNER, Ronald F ; O'DELL, Stephen L

Proceedings of SPIE, the International Society for Optical Engineering, 2010, Vol.7732

Bellingham, Wash: SPIE

Texto completo disponível

Citações Citado por
2
Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)
Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

Forsberg, L. ; Ekström, E. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.352 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Rosengren, V. ; Forsberg, L. ; Ekström, E. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.638 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)
Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

Forsberg, L. ; Ekström, E. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Lantblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.858 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
BUILDING DAMAGE ASSESSMENT WITH DEEP LEARNING
BUILDING DAMAGE ASSESSMENT WITH DEEP LEARNING
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

BUILDING DAMAGE ASSESSMENT WITH DEEP LEARNING

May, S. ; Dupuis, A. ; Lagrange, A. ; De Vieilleville, F. ; Fernandez-Martin, C.

International archives of the photogrammetry, remote sensing and spatial information sciences., 2022, Vol.XLIII-B3-2022, p.1133-1138 [Periódico revisado por pares]

Gottingen: Copernicus GmbH

Texto completo disponível

Citações Citado por
6
Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)
Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

Rosengren, V. ; Ekström, E. ; Forsberg, L. ; Kågström, S. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.612 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)

Ekström, E. ; Rosengren, V. ; Kågström, S. ; Forsberg, L. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.616 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Rosengren, V. ; Ekström, E. ; Forsberg, L. ; Kågström, S. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.623 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Setting the Agenda for Personal Health Records in Low- and Middle-Income Countries
Setting the Agenda for Personal Health Records in Low- and Middle-Income Countries
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Setting the Agenda for Personal Health Records in Low- and Middle-Income Countries

Mwogi, Thomas ; Were, Martin C

Studies in health technology and informatics, 2017, Vol.245, p.1234-1234 [Periódico revisado por pares]

Netherlands

Texto completo disponível

Citações Citado por
10
Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile
Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile

Ekström, E. ; Rosengren, V. ; Kågström, S. ; Forsberg, L. ; Berglund, A. ; Hillert, J. ; Nilsson, P. ; Dahle, C. ; Svenningsson, A. ; Lycke, J. ; Landtblom, A. -M ; Burman, J. ; Martin, C. ; Sundström, P. ; Gunnarsson, Martin ; Piehl, F. ; Olsson, T.

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.626 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (1.708)

Data de Publicação 

De até
Refinar
  1. Antes de1981  (18)
  2. 1981Até1990  (119)
  3. 1991Até2000  (1.355)
  4. 2001Até2011  (3.615)
  5. Após 2011  (1.727)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (6.361)
  2. Alemão  (221)
  3. Japonês  (134)
  4. Francês  (127)
  5. Russo  (36)
  6. Espanhol  (29)
  7. Catalão  (2)
  8. Norueguês  (2)
  9. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.